Johnson & Johnson reported mixed first-quarter results with slight global sales decline but increased earnings, reflecting effective cost management despite challenges from generic competition in the U.S. Management remains optimistic with strong guidance and strategic initiatives in place. The stock may experience a modest positive impact in the short term.

[1]